Discovery and development of AS1411 AS a novel cancer treatment
10.1016/j.yexmp.2009.01.004 · doi-reference
The roles of nucleolin subcellular localization in cancer
10.1016/j.biochi.2015.03.023 · doi-reference
Nucleolin as activator of HPV18 oncogene transcription in cervical cancer
10.1084/jem.20011053 · doi-reference
Overexpression of nucleolin and different expression sites both related to the prognosis of gastric cancer
10.1111/apm.12131 · doi-reference
Proteomic profiling of a mouse model of acute intestinal Apc deletion leads to identification of potential novel biomarkers of CRC
10.1016/j.bbrc.2013.08.076 · doi-reference
Druggable Nucleolin identifies breast tumours associated with poor prognosis that exhibit different biological processes
10.3390/cancers10100390 · doi-reference
Nucleolin: a cell portal for viruses, bacteria, and toxins
10.1007/s00018-022-04300-7 · doi-reference
Cell-surface nucleolin acts as a central mediator for carcinogenic, anti-carcinogenic, and disease-related ligands
10.1007/s00432-014-1587-5 · doi-reference
Midkine and pleiotrophin in neural development and cancer
10.1016/s0304-3835(03)00450-6 · doi-reference
Met-independent hepatocyte growth factor-mediated regulation of cell adhesion in human prostate cancer cells
10.1186/1471-2407-6-197 · doi-reference
Structure and functions of nucleolin
10.1242/jcs.112.6.761 · doi-reference
Exploring the G-quadruplex formation of AS1411 derivatives
10.3390/molecules30081673 · doi-reference
AS1411 binds to nucleolin via its parallel structure and disrupts the exos-miRNA-27a-mediated reciprocal activation loop between glioma and astrocytes
10.1016/j.bbadis.2024.167211 · doi-reference
Construction of highly reactive probes for abasic site detection by introduction of an aromatic and a guanidine residue into an aminooxy group
10.1021/ja904767k · doi-reference
One-pot approach to well-defined biomolecular assemblies by orthogonal Chemoselective ligations
10.1002/ange.200806223 · doi-reference
A new approach for the synthesis of isonitrile carborane derivatives: ligands for metal based boron neutron capture therapy (BNCT) and boron neutron capture synovectomy (BNCS) agents
10.1016/s0162-0134(00)00222-1 · doi-reference
Rhodium (III)-catalyzed intramolecular annulation through C–H activation: total synthesis of (±)-antofine, (±)-septicine, (±)-tylophorine, and rosettacin
10.1002/ange.201204970 · doi-reference
10.1038/nm.1990
10.1038/nm.1990 · doi-reference
Progress in cancer drug delivery based on AS1411 oriented nanomaterials
10.1186/s12951-022-01240-z · doi-reference
Anti-nucleolin aptamer AS1411: an advancing therapeutic
10.3389/fmolb.2023.1217769 · doi-reference
Stable polyvalent aptamer-conjugated NIR fluorescent nanocomposite for cancer imaging and therapy
10.1039/c7tb02218b · doi-reference
Synthesis and application of AS1411-functionalized gold nanoparticles for targeted therapy of gastric cancer
10.1021/acsomega.0c04605 · doi-reference
Cancer-targeted photothermal therapy using aptamer-conjugated gold nanoparticles
10.1016/j.jiec.2018.07.017 · doi-reference
Plasma membrane nucleolin is a receptor for the anticancer aptamer AS1411 in MV4-11 leukemia cells
10.1124/mol.109.055947 · doi-reference
Antiproliferative activity of G-rich oligonucleotides correlates with protein binding
10.1074/jbc.274.37.26369 · doi-reference
Aptamer-based targeted delivery of a G-quadruplex ligand in cervical cancer cells
10.1038/s41598-019-44388-9 · doi-reference
G-quadruplex oligonucleotide AS1411 AS a cancer-targeting agent: uses and mechanisms
10.1016/j.bbagen.2016.12.015 · doi-reference
A synthetic aptamer-drug adduct for targeted liver cancer therapy
10.1371/journal.pone.0136673 · doi-reference
Aptamer-based targeted delivery of functional nucleic acids
10.1021/jacs.3c00841 · doi-reference
In vitro selection of RNA molecules that bind specific ligands
10.1038/346818a0 · doi-reference
Aptamers: a review of their chemical properties and modifications for therapeutic application
10.3390/molecules24234229 · doi-reference
Disposition of TF-PEG-liposome-BSH in tumor-bearing mice
10.1016/j.apradiso.2009.03.018 · doi-reference
Conjugation of the closo-borane mercaptoundecahydrododecaborate (BSH) to a tumour selective peptide
10.1002/zaac.200400064 · doi-reference
Identification, development, synthesis and evaluation of boron-containing nucleosides for neutron capture therapy
10.1016/s0022-328x(99)00085-6 · doi-reference
Reactions of oxonium derivatives of [B12H12]2− with amines: synthesis and structure of novel B12-based ammonium salts and amino acids
10.1016/j.jorganchem.2007.06.001 · doi-reference
Boron agents for neutron capture therapy
10.1016/j.ccr.2019.213139 · doi-reference
Boron delivery agents for neutron capture therapy of cancer
10.1186/s40880-018-0299-7 · doi-reference
Achievements, challenges, and perspectives in the design of boron delivery agents for neutron capture therapy
10.1016/j.ccr.2025.217555 · doi-reference
Evaluation of sodium borocaptate (BSH) and boronophenylalanine (BPA) as boron delivery agents for neutron capture therapy (NCT) of cancer: an update and a guide for the future clinical evaluation of new boron delivery agents for NCT
10.1002/cac2.12582 · doi-reference
Clinical results of long-surviving brain tumor patients who underwent boron neutron capture therapy
10.1016/0360-3016(94)90479-0 · doi-reference
